 Tauopathies
"Tauopathies" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Neurodegenerative disorders involving deposition of abnormal tau protein isoforms (TAU PROTEINS) in neurons and glial cells in the brain. Pathological aggregations of tau proteins are associated with mutation of the tau gene on chromosome 17 in patients with ALZHEIMER DISEASE; DEMENTIA; PARKINSONIAN DISORDERS; progressive supranuclear palsy (SUPRANUCLEAR PALSY, PROGRESSIVE); and corticobasal degeneration.
| Descriptor ID |
D024801
|
| MeSH Number(s) |
C10.574.945
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Tauopathies".
Below are MeSH descriptors whose meaning is more specific than "Tauopathies".
This graph shows the total number of publications written about "Tauopathies" by people in this website by year, and whether "Tauopathies" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 1 | 0 | 1 | | 2012 | 1 | 0 | 1 | | 2013 | 1 | 0 | 1 | | 2016 | 1 | 0 | 1 | | 2022 | 1 | 0 | 1 | | 2023 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Tauopathies" by people in Profiles.
-
Powell WC, Jing R, Walczak MA. Chemical Synthesis of Microtubule-Associated Protein Tau. J Am Chem Soc. 2023 10 04; 145(39):21514-21526.
-
Johnson NR, Yuan P, Castillo E, Lopez TP, Yue W, Bond A, Rivera BM, Sullivan MC, Hirouchi M, Giles K, Aoyagi A, Condello C. CSF1R inhibitors induce a sex-specific resilient microglial phenotype and functional rescue in a tauopathy mouse model. Nat Commun. 2023 01 09; 14(1):118.
-
Kelly JP, Priemer DS, Perl DP, Filley CM. Sports Concussion and Chronic Traumatic Encephalopathy: Finding a Path Forward. Ann Neurol. 2023 02; 93(2):222-225.
-
Johnson NR. Tau acetylation reduces its autophagic degradation and is a targetable pathway for human tauopathies. Bioessays. 2022 06; 44(6):e2200062.
-
Pratt J, Lester E, Parker R. Could SARS-CoV-2 cause tauopathy? Lancet Neurol. 2021 07; 20(7):506.
-
Bayram E, Marras C, Standaert DG, Kluger BM, Bordelon YM, Shprecher DR, Litvan I. Progressive Supranuclear Palsy and Statin Use. Mov Disord. 2020 07; 35(7):1253-1257.
-
Lester E, Parker R. The Tau of Nuclear-Cytoplasmic Transport. Neuron. 2018 09 05; 99(5):869-871.
-
Congdon EE, Lin Y, Rajamohamedsait HB, Shamir DB, Krishnaswamy S, Rajamohamedsait WJ, Rasool S, Gonzalez V, Levenga J, Gu J, Hoeffer C, Sigurdsson EM. Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy. Mol Neurodegener. 2016 08 30; 11(1):62.
-
Meier S, Bell M, Lyons DN, Rodriguez-Rivera J, Ingram A, Fontaine SN, Mechas E, Chen J, Wolozin B, LeVine H, Zhu H, Abisambra JF. Pathological Tau Promotes Neuronal Damage by Impairing Ribosomal Function and Decreasing Protein Synthesis. J Neurosci. 2016 Jan 20; 36(3):1001-7.
-
Levenga J, Krishnamurthy P, Rajamohamedsait H, Wong H, Franke TF, Cain P, Sigurdsson EM, Hoeffer CA. Tau pathology induces loss of GABAergic interneurons leading to altered synaptic plasticity and behavioral impairments. Acta Neuropathol Commun. 2013 Jul 11; 1:34.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|